Different Pharmaceutical Products Need Similar Terminology
- 25 September 2013
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 16 (1) , 11-14
Abstract
In the last decade, discussions on the development of the regulatory framework of generic versions of complex drugs such as biologicals and non-biological complex drugs have attracted broad attention. The terminology used is far from harmonized and can lead to multiple interpretations of legal texts, reflection papers, and guidance documents regarding market introduction as well as reimbursement. This article describes the meaning of relevant terms in different global regions (Europe, USA, WHO) and offers a proposal for a globally accepted terminology regarding (non-) biological complex drugs.Keywords
This publication has 6 references indexed in Scilit:
- Next-Generation Nanomedicines and Nanosimilars: EU Regulators’ Initiatives Relating to The Development and Evaluation of NanomedicinesNanomedicine, 2013
- Nanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studiesRegulatory Toxicology and Pharmacology, 2012
- Biosimilars—why terminology mattersNature Biotechnology, 2011
- Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologicsBiosimilars, 2011
- Large-Scale, Developmentally-Synchronous Caenorhabditis elegans Liquid Cultures Using a New Tangential-Flow Filtration MethodBioProcessing Journal, 2011
- The therapeutic equivalence of complex drugsRegulatory Toxicology and Pharmacology, 2011